Should unaffected female BRCA2 pathogenic variant carriers be told there is little or no advantage from risk reducing mastectomy?
Crossref DOI link: https://doi.org/10.1007/s10689-019-00142-8
Published Online: 2019-08-23
Published Print: 2019-10
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Evans, D. Gareth http://orcid.org/0000-0002-8482-5784
Howell, Sacha J.
Howell, Anthony
Funding for this research was provided by:
Manchester Biomedical Research Centre (IS-BRC-1215-20007)
Text and Data Mining valid from 2019-08-23
Version of Record valid from 2019-08-23
Article History
First Online: 23 August 2019